Kyle Dow

Kyle Dow is a seasoned professional in corporate development and business development with extensive experience in the biotechnology and healthcare sectors. Currently serving as Vice President of Corporate Development at Skyhawk Therapeutics since March 2024, Kyle previously held the position of Vice President of Business Development at Innoviva Specialty Therapeutics, Inc. from July 2022 to March 2024. Earlier, Kyle dedicated over seven years to Entasis Therapeutics, progressing through roles from Director of Business Development to Vice President of Business Development. Additional experience includes serving as Engagement Manager at Health Advances, Consultant at 5AM Ventures, and Product Engineer II at Siemens Healthcare. Kyle holds an M.B.A. from The Wharton School and a Bachelor's Degree in Biomedical Engineering from Rensselaer Polytechnic Institute.